| Clinical and echocardiographic evidence suggesting afterload reduction as a mechanism of action of tolazoline in neonatal hypoxemia. | |
| | |
MedLine Citation:
|
PMID: 6473128 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The effect of tolazoline was assessed in 29 hypoxic neonates. Tolazoline was given in a bolus starting at 1 mg/kg and repeated or infused for 5-134 hours. A "good clinical response," defined as a rise in PaO2 of more than 20 mm Hg, was obtained in 23 (79%), 20 of this group were weaned from the respirator, and three died. Six infants did not respond initially and four died. Failure to respond to tolazoline or to be weaned from the ventilator was usually associated with severe additional pathology. Urine output (greater than 1 ml/kg/h) was adequate in most neonates during therapy. In those with preexisting oliguria (less than 1 ml/kg/h), output improved during therapy. Blood pressure monitoring showed a fall in blood pressure in 19 patients during tolazoline administration, but true hypotension only occurred in four; in seven there was no fall and in three there was a rise in blood pressure. Echocardiography was performed prior to therapy in 19 patients and repeated in 12 patients after 24 h. Additional "tracking" was performed at 10 min, 1 h, and 4 h in seven patients. Prior to therapy, right ventricular dysfunction was demonstrated by abnormal right ventricular systolic time intervals (RVSTIs) in 17 of the patients tested. A rapid improvement was evident during therapy especially with "tracking." Left ventricular dysfunction, assessed by left ventricular systolic time intervals (LVSTIs), ejection fraction (EF), shortening fraction (SF), and velocity of circumferential fiber shortening (VCF), was also evident prior to therapy and improved, though more gradually than the RVSTIs.(ABSTRACT TRUNCATED AT 250 WORDS) |
| | |
Authors:
|
G G Sandor; A J Macnab; F A Akesode; V J Ebelt; M R Pendray; W Y Ling; M W Patterson; M A Tipple |
Related Documents
:
|
2011848 - Significance of the subvalvular apparatus for left-ventricular dimensions and systolic ... 7813308 - Role of pericardial constraint for right ventricular function in humans. 6234438 - Metabolic and contractile function enhancement during rat heart postnatal development. 8546218 - Antioxidant and oxidative stress changes during heart failure subsequent to myocardial ... 7014098 - Effects of endotracheal suction versus apnea during interruption of intermittent or con... 10775558 - Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Pediatric cardiology Volume: 5 ISSN: 0172-0643 ISO Abbreviation: Pediatr Cardiol Publication Date: 1984 Apr-Jun |
Date Detail:
|
Created Date: 1984-10-24 Completed Date: 1984-10-24 Revised Date: 2008-02-20 |
Medline Journal Info:
|
Nlm Unique ID: 8003849 Medline TA: Pediatr Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 93-9 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anoxia
/
drug therapy* Blood Pressure / drug effects Cardiac Output / drug effects Diuresis / drug effects Echocardiography* Hemodynamics / drug effects* Humans Infant, Newborn Infant, Premature, Diseases / drug therapy* Myocardial Contraction / drug effects Oxygen / blood Prognosis Tolazoline / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
59-98-3/Tolazoline; 7782-44-7/Oxygen |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Myocardial disease in Rocky Mountain spotted fever: clinical, functional, and pathologic findings.
Next Document: Nosocomial transmission of hepatitis A from a hospital-acquired case.